Moleculin skyrockets on interim data for annamycin MB-106 trial
Shares of US clinical-stage drugmaker Moleculin Biotech (Nasdaq: MBRX) were going through the roof, leaping 1,228% to $6.11 in early trading, as the company updated on its lead candidate’
Moleculin provided a preliminary update on recent clinical activity and expected near term milestones for its lead program annamycin MB-106 for the treatment of acute myeloid leukemia (AML) following its fiscal year 2023 filing with the Securities and Exchange Commission.
The company said it is preparing for an End of Phase II meeting with the US Food and Drug Administration (FDA) and anticipates starting a pivotal registration study as a second-line therapy in AML before the end of 2024. This could position AnnAraC for an accelerated approval pathway.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze